

COMPANY ANNOUNCEMENT

KarmelSonix Receives European CE Mark for its Cough Detector

HIGHLIGHTS

- KarmelSonix has received CE Mark for the PulmoTrack® - 3010 – CoughCount™ (CC).
- The PulmoTrack-CC™ has been certified within the scope of the PulmoTrack® and Personal WheezoMeter™, which have been previously approved by the CE.
- The CoughCount™ algorithm and software will be sold as an add-on option.
- Application for the CC in Australia will now be made through the TGA.
- In other European news, the European Respiratory Society (ERS) has accepted for presentation 5 scientific abstracts relating to KSX technology.

22nd July 2009: The Directors of KarmelSonix Ltd (KSX or the Company) are pleased to announce the receipt of the CE Mark for the PulmoTrack® 3010 CoughCount™ (CC). The certification according to Annex II.3 of the Council Directive 93/42/EEC allows the sale and use of KarmelSonix’ cough detection module in the European Union. The PulmoTrack-CC™ uses the PulmoTrack® 2010 as the data acquisition device but facilitates detection, counting and documentation of coughs. The PulmoTrack® 3010 CC has been submitted for FDA approval for distribution of the option in the US market and will shortly be submitted for Australian, TGA approval.

The PulmoTrack-CC™ is the first cough detection and counting device to receive CE Mark Certification. It uses elaborate algorithms to identify coughs and differentiate between true coughs and other signals such as speech, crying and snoring. The high level of accuracy of the detection was presented recently at the ATS conference in San-Diego. It is also an important component of the Wholter™ ambulatory monitor for asthma and COPD Management.

Commenting on this latest product “add on” approval, KSX Vice President, Sales & Marketing Mr. Larry Murdock; said “adding the objective measurement of cough is an important contribution to our product offering. The ability to connect cough to sleep arousal will benefit patients with unexplained sleep disorders whose cough disrupts the quality of sleep. The PTC-CC is also a fantastic extension to the PulmoTrack® and WHolter™ products, and their ability to qualify and quantify wheezing. Combining PT-CC and WheezeRATE™ will benefit laboratories performing airway challenge testing, and ambulatory evaluations in the home and workplace.”

Additionally, the European Respiratory Society (ERS) recently notified KSX and its Scientific Investigators that it has accepted for presentation at its forthcoming meeting in September where KSX products will again be showcased, 5 abstracts prepared by the Company which utilise its technology.

“Wheeze Rate – A New Paradigm in Asthma Management”

The Abstract titles are as follows:

- (i) **Acoustic Transmission Airway Monitoring during Mannitol Challenge Test**
Alfred Hospital and Monash University, Melbourne, Australia;
- (ii) **Acoustic Transmission Airway Monitoring During Exacerbation of Asthma**
Alfred Hospital and Monash University, and PulmoSonix Pty Ltd Melbourne, Australia;
- (iii) **Cough Monitoring during Bronchodilator Administration in Paediatric Asthma.**
Department of Pediatrics, Carmel Medical Center, and the Technion, Haifa, Israel.
- (iv) **Children with nocturnal asthma wheeze intermittently during sleep**
Pediatric Department, University of Verona, Verona, Italy; KarmelSonix Ltd., Haifa, Israel and Institute of Pulmonology, Hadassah-Hebrew University, Jerusalem, Israel.
- (v) **Inspiratory wheezes and intra-thoracic inspiratory flow limitation**
Rappaport Faculty of Medicine, Technion and KarmelSonix Ltd. Haifa, Israel

For additional information please contact:

Mr. Peter Marks, Chairman	+61 (0)3 9824 8166	Peter@karmelsonix.com
Prof. Noam Gavriely, Director	+972 544 661 337	Noam@karmelsonix.com

KarmelSonix Ltd. focuses on supplying innovative non-invasive acoustic tools for disease management of asthma and related pulmonary disorders. Asthma affects 6-16% of the population in developed countries with a cost exceeding \$US15 billion in the US alone.

Acoustic Asthma Management is a breakthrough in monitoring of the asthmatic patient of all ages, including the very young, very old and others who cannot perform currently available tests. The technology that comes from extensive R&D and clinical validation in the US, Israel and Australia, facilitate continuous monitoring of patients at home, in the ICU and even during sleep. The company is focused on early commercialization of its products with special emphasis on the European and North American markets.

“Wheeze Rate – A New Paradigm in Asthma Management”